Prospective Validation of Prognostic Score in High-Grade Gastrointestinal Neuroendocrine Carcinomas (GI-NECs) Abstract #1492

Introduction: Prognostic markers for risk-stratification of GI-NECs are lacking.
Aim(s): We aimed to validate our prognostic score for GI-NECs (liver metastases, alkaline phosphatase, lactate dehydrogenase, ECOG performance status (PS) and Ki67; Lamarca et al, ASCO 2015).
Materials and methods: We prospectively identified all consecutive patients (pts) diagnosed with GI-NECs seen at The Christie (July’14-Nov’15). Our previously designed score was applied. Cox regression and Kaplan Meier were used for survival analysis.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr Angela Lamarca

To read results and conclusion, please login ...

Further abstracts you may be interested in

#33 Survival of Neuroendocrine Tumour Patients in Newcastle NHS Foundation Trust
Introduction: Neuroendocrine tumors (NETs) are rare neoplasms, with an incidence of 2-2.4 per 100,000, which derive from the neurones and epithelial cells of the diffuse neuroendocrine system. Neuropeptide-secreting NETs may present with overt clinical symptoms including abdominal pain, flushing and diarrhoea, whereas non-functioning NETs may be asymptomatic or present with obstructive symptoms. In Newcastle NHS Foundation Trust, NET patients are managed with a multi-disciplinary approach, according to UK and European NET guidelines.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Andy James
Authors: Hearn K, Teo L, Bernstone G, Johnson S, ...
#408 Expression of Cocaine- and Amphetamine-Regulated Transcript is Associated with Worse Survival in Small Bowel Carcinoid Tumors
Introduction: Cocaine- and amphetamine-regulated transcript (CART) peptide acts both as a neurotransmitter and hormone. We recently demonstrated that CART is expressed in several types of neuroendocrine tumors.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Kalle Landerholm
#445 Comparison of Prognostic Capacity for Overall Survival (OS) and Disease-Free Survival (DFS) of Neuroendocrine Tumors (NETs) Classifications: 2010 WHO, TNM Staging-ENETS and AJCC
Introduction: Current NETs classifications are: WHO, ENETS and AJCC. No consensus exists about which one more accurately predicts NET outcomes.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dra Nuria Mulet-Margalef
#470 Overall Survival of Well-Differentiated Neuroendocrine Tumors Evaluated by F-18-FDG-PET
Introduction: Today, grading, and thereby choice of treatment strategy for patients with neuroendocrine (NE) tumors, is mainly based on the proliferation index, Ki-67. As a supplement to this pathological evaluation, a whole body image analysis could be of value.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MSc, PhD Tina Binderup
#575 Does the ENETS TNM staging criteria predict survival in patients with small bowel neuroendocrine tumours?
Introduction: A TNM staging system was designed by ENETS to stage small bowel NETs .(SBNETs)
Conference: 10th Annual ENETS Conference (2013)
Category: Clinical
Presenting Author: Dr Rajaventhan Srirajaskanthan
Keywords: Staging
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.